CARAFATE SUSPENSION Rx
Generic Name and Formulations:
Indications for CARAFATE SUSPENSION:
Short-term (up to 8 weeks) treatment of active duodenal ulcer. Maintenance of healed duodenal ulcers (tabs only).
Active: 1g 4 times daily on an empty stomach for 4–8 weeks. Maintenance: 1g 2 times daily.
Susp: administer by oral route only; do not give intravenously. Monitor for glycemia in diabetic patients. Chronic renal failure. Dialysis. Tabs: swallowing impairment (eg, recent or prolonged intubation, tracheostomy, history of aspiration, dysphagia, others). Pregnancy (Cat.B). Nursing mothers.
Avoid antacids within 30mins of dosing. May reduce absorption of tetracyclines, quinidine, levothyroxine, phenytoin, cimetidine, digoxin, ciprofloxacin, norfloxacin, ketoconazole, ranitidine, theophylline; dose concomitant drugs 2hrs before sucralfate. Additive aluminum load with aluminum-containing antacids. Monitor warfarin.
Endocrinology Advisor Articles
- Higher BUN May Increase Risk for Incident Diabetes
- Efficacy of Novel GLP-1 Receptor Agonist Drug Device Examined
- Takeout Food May Increase Adverse Health Consequences in Children
- Nonhormonal Options Available for Menopause Symptom Relief
- Plasma Volume Changes Mediate Risk of CV Mortality With Empagliflozin
- New Consensus Recommendations on Use of Continuous Glucose Monitoring
- Does Genetic Susceptibility Lead to Late-Onset Type 1 Diabetes?
- Clinical Outcomes in T2D: Low-Carbohydrate vs Calorie-Restricted Diet
- New Continuous Glucose Monitoring System Now Available for Medicare Patients
- Text Message-Delivered Interventions Effective for Weight Management
- Effect of Intra-Articular Depot Betamethasone on Insulin Resistance in T2D
- Gastric Bypass vs Sleeve Gastrectomy Outcomes in Morbid Obesity
- Acute Kidney Injury Increases Risk for Postdischarge Hypoglycemia in Diabetes
- Novel Deep Learning System May Help Identify Diabetic Retinopathy
- Trends in CVD, Risk Factors, and Medications in Children With T1D